🔴 ACADIA Pharmaceuticals is trading 4.04% down today after RADIANT missed primary endpoint

ACADIA Pharmaceuticals is trading at $19.84 (-4.04%) as the RADIANT 60 mg dose narrowly missed the primary endpoint (p=0.0603).

• The dose showed nominal significance on a key secondary measure.
• ACADIA fell 12.78% on September 24 and 6.76% on September 25. The Nasdaq is down 0.59%; the trial result is the clearer company-specific catalyst for the ongoing weakness.